Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9B

Why It Matters

The deal gives Chiesi a differentiated oral HAE therapy, expanding its rare‑disease footprint and accelerating revenue growth toward its $7 billion target, while intensifying competition in a market poised for innovative treatments.

Key Takeaways

• Chiesi to acquire KalVista for $1.9 bn, paying $27 per share
• Ekterly, first oral on‑demand HAE therapy, generated $49.1 m revenue in 2025
• Ekterly captured ~20% of U.S. HAE market within months of launch
• Chiesi aims for $7 bn revenue by 2030, with rare disease driving growth
• Competition intensifies as gene‑editing and prophylactic oral drugs enter HAE space

Pulse Analysis

Chiesi’s $1.9 billion acquisition of KalVista underscores the Italian group’s aggressive push into rare‑disease therapeutics. With a 40.3% premium, the deal adds an oral, on‑demand HAE treatment to a portfolio that already includes skin‑disease drug Filsuvez and enzyme‑replacement therapy Elfabrio. The purchase aligns with Chiesi’s stated ambition to hit $7 billion in revenue by 2030, leveraging the higher margins and faster growth rates typical of specialty biotech assets.

Ekterly’s market entry has been unusually rapid. After FDA approval last summer, the drug posted $49.1 million in 2025 sales and captured roughly one‑fifth of the U.S. acute‑treatment segment, a testament to physician and patient preference for an oral pill over injectable alternatives. The product’s mechanism—kallikrein inhibition—offers a distinct pathway from existing prophylactic injectables, positioning it as a preferred on‑demand option. Yet the HAE arena is heating up, with competitors like Pharvaris advancing oral bradykinin‑B2 antagonists and gene‑editing firms such as Intellia moving toward potential one‑time cures.

The broader HAE landscape illustrates a shift toward patient‑centric, less invasive therapies, a trend that investors are watching closely. As oral agents and gene‑editing approaches mature, pricing dynamics and reimbursement strategies will evolve, potentially reshaping market share distribution. For Chiesi, integrating Ekterly not only diversifies its rare‑disease pipeline but also provides a platform for future combination or label‑expansion studies, especially as the company eyes pediatric approvals. The acquisition therefore represents both a near‑term revenue boost and a strategic foothold in a rapidly innovating therapeutic niche.

Deal Summary

Chiesi Group announced a $1.9 billion cash acquisition of KalVista Pharmaceuticals, paying $27 per share, a 40.3% premium. The deal adds KalVista's oral HAE drug Ekterly to Chiesi's rare-disease portfolio and is expected to close in the third quarter of 2026.